BRIEF published on 09/15/2026 at 15:40, 25 days 11 hours ago Revive Therapeutics Aims to Expand Bucillamine Portfolio Intellectual Property Orphan Diseases Medical Countermeasures Government Partnerships Bucillamine
PRESS RELEASE published on 09/15/2026 at 15:35, 25 days 11 hours ago Revive Therapeutics to Expand Bucillamine IP and Orphan Drug Portfolio Across Medical Countermeasures and Rare Diseases Revive Therapeutics Ltd. outlines strategy to build protected bucillamine franchise for medical countermeasures, rare diseases, and government preparedness programs Rare Diseases Medical Countermeasures Revive Therapeutics Ltd. Bucillamine Franchise Government Preparedness
BRIEF published on 08/19/2026 at 20:40, 1 month 22 days ago Revive Therapeutics Proposes Shares for Debt Settlement Debt Settlement Canadian Securities Exchange Shares Issuance Revive Therapeutics Biodefense Research
PRESS RELEASE published on 08/19/2026 at 20:35, 1 month 22 days ago Revive Therapeutics Announces Proposed Shares for Debt Settlement Revive Therapeutics Ltd. announces proposed debt settlement by issuing Settlement Shares to settle outstanding trade payables. Subject to CSE approval Debt Settlement Settlement Shares CSE Approval Revive Therapeutics Ltd. Biodefence
BRIEF published on 08/19/2026 at 14:45, 1 month 22 days ago Revive Therapeutics Advances Biodefence Strategy with Bucillamine Medical Countermeasures Pandemic Preparedness Government Partnerships Bucillamine Biodefence
PRESS RELEASE published on 08/19/2026 at 14:40, 1 month 22 days ago Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio Revive plans to expand bucillamine use in biodefence with positive DRDC findings, government opportunities, and complementary therapies, focusing on medical countermeasures Bucillamine Biodefence Revive DRDC Government Opportunities
BRIEF published on 08/15/2026 at 00:55, 1 month 27 days ago Revive Therapeutics Grants 15.5 Million Stock Options Stock Options Life Sciences Biodefense Pandemic Preparedness Revive Therapeutics
PRESS RELEASE published on 08/15/2026 at 00:50, 1 month 27 days ago Revive Therapeutics Reports Grant of Options Revive Therapeutics Ltd. authorized the grant of 15,500,000 incentive stock options to key team members. The options aim to drive performance and incentivize excellence in advancing corporate objectives Stock Options Incentive Pandemic Preparedness Revive Therapeutics Ltd. Biodefence
BRIEF published on 08/12/2026 at 14:00, 1 month 29 days ago Revive Therapeutics Announce Positive Study Results on Bucillamine for Nerve-Agent Exposure Bucillamine Revive Therapeutics Nerve-agent Research DRDC Study Biodefence
PRESS RELEASE published on 08/12/2026 at 13:55, 1 month 29 days ago Revive Therapeutics Reports Positive Results from DRDC Bucillamine Nerve-Agent Research Study Revive Therapeutics announces positive results from DRDC research study on bucillamine in nerve-agent exposure model, showing preservation of GABA receptors. Further studies planned Bucillamine Revive Therapeutics DRDC Research Study Nerve-agent Exposure GABA Receptors
Published on 10/10/2026 at 04:45, 22 hours 6 minutes ago Immutable Holdings and Jorge Masvidal's Gamebred Fighting Championship (FC) Enter Into Definitive Agreement for Proposed Reverse Takeover Transaction and Listing on the TSXV
Published on 10/10/2026 at 02:03, 1 day ago BrandPilot AI Announces Closing of Previously Announced Debt Settlement
Published on 10/10/2026 at 02:00, 1 day ago Battery X Metals Reports Estimated Driving Range Increase of Approximately 101 Kilometers Following a Single-Electric-Vehicle Performance Evaluation of Next-Generation Patent-Pending Lithium-Ion Battery Rebalancing Technology
Published on 10/09/2026 at 23:00, 1 day 3 hours ago Trans Canada Gold Closes First Tranche of Non-Brokered Private Placement for Gross Proceeds of CDN $2,144,720
Published on 10/09/2026 at 22:15, 1 day 4 hours ago Loop Industries to Host Second Quarter Fiscal 2027 Earnings Conference Call
Published on 10/10/2026 at 16:35, 10 hours 16 minutes ago New Opportunities for Global Cooperation: Kexing Biopharm Shines at CPHI Milan 2026
Published on 10/10/2026 at 16:30, 10 hours 21 minutes ago ZPMC-Built Infrastructure Supports China's First Offshore Wind Project to Deploy 18 MW Turbines at Scale
Published on 10/10/2026 at 10:05, 16 hours 46 minutes ago ONLYOFFICE 10.0 brings AI tools, modular apps, and stronger security to its open-source office suite
Published on 10/09/2026 at 21:24, 1 day 5 hours ago Branicks Group AG: Extraordinary General Meeting does not approve all items on the agenda
Published on 10/09/2026 at 21:17, 1 day 5 hours ago EQS-Adhoc: Branicks Group AG: Agenda topic four at extraordinary general meeting rejected
Published on 10/09/2026 at 19:27, 1 day 7 hours ago Disclosure of transactions in own shares from October 1 to October 9, 2026
Published on 10/08/2026 at 18:30, 2 days 8 hours ago Cegedim: Release of its 2026 Interim Financial Report
Published on 10/08/2026 at 18:00, 2 days 8 hours ago Launch of LINK, the next generation of THIN: Clinityx’s first European Health Data Warehouse, approved by the French Data Protection Authority for 10 years
Published on 10/08/2026 at 17:45, 2 days 9 hours ago Carrefour announces a real estate sale and leaseback transaction involving 35 stores in France and Spain
